Sector News

Sanofi signs agreement to acquire Kiadis Pharma for $359m

November 6, 2020
Life sciences

Sanofi has signed a definitive agreement to acquire the entire share capital of Kiadis Pharma in a deal valued at approximately €308m ($359m).

Under the agreement, Sanofi will offer €5.45 per share to Kiadis Pharma, a clinical-stage company developing cell-based immunotherapy products.

The acquisition will give Sanofi full control of next-generation natural killer (K-NK) cell platform and pipeline of cell-based cancer immune-therapeutics and infectious disease treatments.

The K-NK cell platform derives from allogeneic or ‘off-the-shelf’ NK cells from a healthy donor and these cells hunt for malignant cancer cells.

It can potentially make products rapidly and economically available for a broad range of indications.

Under the deal, Kiadis will develop NK cell-based medicines alone or with Sanofi’s existing platforms.

Furthermore, the research, development and commercial expertise of Sanofi will be leveraged to advance Kiadis’ pipeline that includes NK cell-based medicines.

Sanofi Research & Development global head John Reed said: “We believe the Kiadis ‘off the shelf’ K-NK cell technology platform will have broad application against liquid and solid tumours, and create synergies with Sanofi’s emerging immuno-oncology pipeline, providing opportunities for us to pursue potential best-in-disease approaches.”

On completion of the public offer, Sanofi will provide the resources and capabilities needed for boosting the development of Kiadis’ programmes.

Kiadis’ pipeline of NK cell therapies includes K-NK002, K-NK003 and KNK-ID-101.

KNK-ID-101 is a programme analysing the properties of K-NK cells and their suitability to fight SARS-CoV-2. It will also analyse whether the cells can be used as a post-exposure pre-emptive therapy for Covid-19 in high-risk patients.

The company anticipates initiating a Phase I / IIa trial evaluating the use of K-NK cells to treat covid-19 patients with government grant funding.

In July, the company licensed Kiadis’ pre-clinical K-NK004 programme for potential combination for multiple myeloma.

by Pharmeceutical-technology.com

Source: pharmaceutical-technology.com

Related News

April 17, 2021

Thermo Fisher to buy research contractor PPD in $17B deal

Life sciences

Thermo Fisher Scientific plans to buy PPD for $17.4 billion to bolster its clinical research service offerings to pharmaceutical and biotech companies.

April 17, 2021

Nestlé finds supplement cocktail slashes preterm birth in major preconception study

Life sciences

Nestlé Research has linked a specific blend of myo-inositol (a type of sugar), probiotics, riboflavin, zinc and vitamins D, B6 and B12 to the decreased incidence of preterm birth when consumed before and during pregnancy.

April 17, 2021

Eli Lilly, riding pharma’s rising digital wave, drafts Apple exec to replace Shah as CDO

Life sciences

Eli Lilly hired a new digital chief from Apple in another consumer switch for pharma and as the industry speeds up its shift to online strategies.

Send this to a friend